Jan 30, 2026 07:25AM
May 7, 2025 08:16AM
Mar 26, 2024 10:25AM
Mar 26, 2024 10:25AM
Aug 15, 2023 07:25AM
Aug 15, 2023 07:25AM
Jul 26, 2023 07:25AM Alterity Therapeutics (ATHE) Announces Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Jul 26, 2023 07:25AM
Apr 26, 2023 07:25AM
Apr 26, 2023 07:25AM
Apr 4, 2023 07:25AM
Mar 16, 2023 07:25AM
Mar 8, 2023 07:25AM
Feb 16, 2023 04:46PM Alterity Therapeutics (ATHE) Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
Feb 16, 2023 04:44PM
Jan 30, 2023 07:29AM
Jan 30, 2023 07:25AM
Jan 25, 2023 07:26AM
Jan 25, 2023 07:25AM
Jan 9, 2023 10:26AM
Jan 9, 2023 10:25AM Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Nov 7, 2022 10:26AM
Nov 7, 2022 10:25AM
Oct 28, 2022 07:25AM
Oct 26, 2022 07:25AM
Oct 13, 2022 10:27AM
Oct 13, 2022 10:25AM
Sep 26, 2022 07:25AM Alterity (ATHE) Presents Wearable Sensor Data from the bioMUSE Natural History Study
Sep 26, 2022 07:25AM
Sep 20, 2022 07:26AM
Sep 20, 2022 07:25AM
Aug 25, 2022 07:25AM
Jul 22, 2022 07:25AM
Jul 6, 2022 11:00AM
Jun 23, 2022 11:00AM Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Jun 2, 2022 08:00AM
Apr 27, 2022 07:41AM
Apr 27, 2022 07:40AM
Apr 6, 2022 09:34PM
Jan 28, 2022 07:08AM
Jan 28, 2022 07:08AM
Jan 27, 2022 07:45AM Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Dec 14, 2021 07:25AM
Dec 14, 2021 07:25AM
Nov 9, 2021 07:30AM
Nov 5, 2021 02:57AM
Nov 4, 2021 07:30AM
Oct 29, 2021 02:50AM
Oct 19, 2021 05:10PM Alterity Therapeutics (ATHE) Expands ATH434 Phase 2 Clinical Development Program
Oct 19, 2021 05:08PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All